AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02819960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT02534116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC) therapy
Description: Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
Study NCT02534116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
Study NCT03223467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
Study NCT00506597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
Study NCT01336751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: solution for subcutaneous injection
Study NCT01336751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Description: suspension for subcutaneous injection
Study NCT02037386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-side branch stent
Description: Implantation of H-side branch stent at coronary bifurcation stenotic lesion
Study NCT04439617 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood examination
Description: use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
Study NCT01022359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TesioCath
Description: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
Study NCT01022359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeCath Twin
Description: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
Study NCT03452033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H-1337 Placebo
Description: H-1337 Placebo Vehicle
Study NCT03452033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [1]
Description: H-1337 Ophthalmic Solution Concentration 1
Study NCT03452033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [2]
Description: H-1337 Ophthalmic Solution Concentration 2
Study NCT03452033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [3]
Description: H-1337 Ophthalmic Solution Concentration 3
Study NCT00787137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG102
Description: A single intravenous infusion
Study NCT00787137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Phosphate-buffered saline
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Use BCG website
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention
Description: Use passive website
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02869412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02761694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.
Study NCT02761694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as an intramuscular (IM) injection.
Study NCT02761694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous (IV) infusion.
Study NCT04741191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Description: Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.
Study NCT04741191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
Study NCT05828420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
Study NCT05828420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart sound
Description: Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
Study NCT05828420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
Study NCT00003963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
Study NCT00003963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated.
Study NCT02513823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2,000 International Units (IU)of vitamin D3
Description: 2,000 IU vitamin D taken daily for 10 weeks
Study NCT00740714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 with vitamin E
Description: 2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
Study NCT00740714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo with vitamin E
Description: placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
Study NCT03628638 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
Study NCT03002688 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
Study NCT05006209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One visit root canal treatment
Study NCT05006209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two visit root canal treatment
Study NCT01778322 — intervention group
Intervention type: PROCEDURE
Intervention: Intracranial aneurysm embolization
Description: Treatment of intracranial aneurysms
Study NCT01961960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: intramuscular
Study NCT00359567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Study NCT00359567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron hydrochloride
Description: intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Study NCT02980744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention
Description: The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
Study NCT01902888 — intervention group
Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis
Study NCT02448888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted exercise
Description: 2 months, 3 times/week
Study NCT02448888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General exercise recommendations
Description: 2 months, 3 times/week
Study NCT00085254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT00085254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00085254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00085254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00085254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01342744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin(850 mg) 1tab oral twice aday
Study NCT01342744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tab oral twice a day
Study NCT00319657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation
Description: Transplantation of hematopoietic stem cells from the living donor.
Study NCT00319657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
Study NCT02818114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Enhanced Prolonged Exposure
Description: Peer support interventions as adjunct to prolonged exposure
Study NCT04180683 — intervention group
Intervention type: OTHER
Intervention: Battery of screening tests with semi-structured interview
Description: First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
Study NCT04180683 — intervention group
Intervention type: OTHER
Intervention: Battery of screening tests without semi-structured interview
Description: First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
Study NCT01989793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan will be given in increasing doses to those in the losartan arm.
Study NCT01989793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to those in placebo arm
Study NCT04817020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: %2 Klorheksidin
Description: Effect on phlebitis
Study NCT00939016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lunch meal with 24 hour dietary recall
Description: Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
Study NCT06107712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face yoga exercise
Description: The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.
Study NCT03876912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: 18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
Study NCT02101645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodical low intensity direct current (LIDC) stimulation of wound.
Description: Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
Study NCT02101645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compression therapy of swollen limbs.
Description: Compression bandage is used for reducing swelling of the limbs.
Study NCT04251598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Am Protecting My Child from the Sun
Description: The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband.
Study NCT04251598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS for sun protection
Description: While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
Study NCT04482842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene detection (CYP2C9*3, VKORC1)
Description: Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
Study NCT04482842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: Warfarin is administered at a gene-guided dose or at a regular dose.
Study NCT04482842 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin Sodium
Description: Warfarin is administered at a gene-guided dose or at a regular dose.
Study NCT03414424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.
Study NCT03414424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study NCT04028206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxymethylbutyrate
Description: Hydroxymethylbutyrate supplementation at 3.0 g/day with dietary advice.
Study NCT04028206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude High Frequency Vibration (LMHFV)
Description: Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone showed that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
Study NCT04028206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Elastic-band Exercise
Description: Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed exercises 3 times per week, one hour after HMB intake, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by a qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching.
Study NCT03833973 — intervention group
Intervention type: BEHAVIORAL
Intervention: Overtraining Monitoring
Description: Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
Study NCT02728895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab Injection.
Study NCT03863223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, Trastuzumab, Docetaxel
Description: Pyrotinib 400mg orally daily until progressive disease
Study NCT03863223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Trastuzumab, Docetaxel
Description: Placebo 400mg orally daily until progressive disease
Study NCT00970983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadrantectomy and axillary dissection
Description: standard quadrantectomy and axillary dissection
Study NCT00970983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadrantectomy + sentinel node biopsy
Description: standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
Study NCT04214886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is an anti-cancer drug acting as an antimetabolite that is used to treat leukemia and lymphoma cancers.
Study NCT02160600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard multiphase CT
Study NCT02160600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: split bolus Dual energy CT